Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


CSPI, Public Citizen on FDA

This article was originally published in The Tan Sheet

Executive Summary

The Center for Science in the Public Interest and Public Citizen assert that the White House and Congress have "hampered the agency," in a June 27 release. The consumer groups charge that the Administration is at fault for causing FDA to be without a permanent commissioner "for roughly 70% of the Bush presidency" and that Congress has "abdicat[ed] much of its oversight responsibility" as well as "slash[ed] the headquarters staffing" of the agency's Center for Food Safety & Applied Nutrition by 11% since 1978. CSPI and Public Citizen point out that FDA's civil servants need more resources to do their jobs effectively and present a litany of concerns about certain agency programs and practices that are under-performing or problematic. Public Citizen cites FDA's lack of enforcement action on companies marketing unapproved nicotine-containing beverages for smoking cessation as dietary supplements and criticizes the drug and device user fee systems. The agency's food-related "failures" include the "misleading" qualified health claims program...

You may also be interested in...

Neuroscience Challenges Oncology For Top Spot In CDER’s 2019 Novel Approvals

Oncology R&D isn’t waning, but investment in neurology and psychiatry drug development are paying off in new drug approvals. Rapid growth in CDER non-malignant hematology approvals reflects longer, broader trend toward orphan drugs.

In Case You Missed It … News On China Patents, EMA Chief, And More

We clean out your Martin Luther King Day inbox so you don't have to.

At Muted J.P. Morgan, Focus Is Execution, But US Pricing Is Persistent Overhang

Political worries aside, industry is confidently executing on focused strategies as it welcomes a new decade, even if a lack of deal news at the J.P. Morgan Healthcare Conference didn't excite investors.





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts